De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials

Marco Valgimigli(University of Bern), Myeong‐Ki Hong(Yonsei University), Sung‐Jin Hong(Inje University Sanggye Paik Hospital), Zhen Ge(Nanjing Medical University), Felice Gragnano(Ospedale Sant'Anna), Peter Jüni(University of Oxford), Dominick J. Angiolillo(University of Florida), Gregg W. Stone(Cardiovascular Institute of the South), Young Bin Song(Samsung Medical Center), Dik Heg, Stephan Windecker(University of Bern), George Dangas(Mount Sinai Hospital), Shamir R. Mehta(Population Health Research Institute), Pascal Vranckx(Jessa Hospital), Sergio Leonardi(Policlinico San Matteo Fondazione), Renato D. Lópes(Duke University), Bruno R. da Costa(University of Oxford), Konstantina Chalkou(University of Bern), Hyeon‐Cheol Gwon(Samsung Medical Center), Joo‐Yong Hahn(Samsung Medical Center), Anna Franzone(Federico II University Hospital), Usman Baber(University of Oklahoma Health Sciences Center), Michael C. Gibson(Beth Israel Deaconess Medical Center), Shao-Liang Chen(Nanjing Medical University), Eugène McFadden(Skadden Arps Slate Meagher & Flom), Paolo Calabrò(University of Campania "Luigi Vanvitelli"), Byeong‐Keuk Kim(Yonsei University), Roxana Mehran(Mount Sinai Hospital), Yangsoo Jang(Yonsei University)
The Lancet
August 31, 2024
Cited by 93


Related Papers